Navigation Links
ASTRO participates in FDA meeting on radiation safety
Date:6/16/2010

The American Society for Radiation Oncology (ASTRO) continued to advance its Target Safely initiative by participating in the Food and Drug Administration's (FDA) public meeting on Device Improvements to Reduce the Number of Under-Doses, Over-Doses, and Misaligned Exposures from Therapeutic Radiation on June 9 and 10. ASTRO commends the FDA on holding this meeting to identify current issues and further develop data, which will help inform the FDA's actions to ensure the highest level of safety for radiation therapy patients.

Numerous experts from the radiation therapy community, including those from clinical practice, academia and the device industry, gathered to address safety in radiation therapy. Meeting sessions looked at specific issues with device improvements and reporting, user training, and quality assurance. Eight ASTRO members, Lawrence Marks, M.D., Bruce Thomadsen, Ph.D., Todd Pawlicki, Ph.D., Eleanor Harris, M.D., Jeff Michalski, M.D., M.B.A., Prabhakar Tripuraneni, M.D., FASTRO, Eric Ford, Ph.D., and Benedick Fraass, Ph.D., FASTRO, gave presentations discussing the potential benefits of enhanced collaboration between device users and industry to improve usability, adding safety features to improve radiotherapy devices, and the need for a national medical event reporting system for radiotherapy administrations.

Presenters addressed challenges in keeping quality assurance protocols aligned with advances in technology, while acknowledging the important role that new technology can play in supporting quality assurance.


'/>"/>

Contact: Nicole Napoli
nicolen@astro.org
703-839-7336
American Society for Radiation Oncology
Source:Eurekalert

Page: 1

Related medicine news :

1. ASTRO, ACR issue IGRT, SBRT guidelines
2. Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity
3. 5,000 deaths: A catastrophic, regrettable decision in Belgium
4. Does Glutathione-S-transferase associate with gastrointestinal cancer in Korean population?
5. Why does percutaneous endoscopic gastrostomy fail to eliminate gastroesophageal reflux?
6. Senate Committee Advances Disastrous Idaho Health Freedom Act
7. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
8. ASTRO awards 17 Advocacy Day travel grants
9. ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
10. Santa Monica Jury Rejects Claims of Catastrophic Brain Injury From Exposure to Mold; Plaintiff Faces Motions for Attorney Fees and Costs
11. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... White Plains, NY (PRWEB) , ... March 27, 2017 , ... ... honoring Root Canal Awareness Week by teaching their patients about the key role this ... canal therapy from an experienced endodontist. To better serve those who need a ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... LEXINGTON, Mass. , March 27, 2017   Pulmatrix, ... innovative inhaled therapies to address serious pulmonary diseases, today announced ... allergic fungal disease, cystic fibrosis and asthma to its ... Richard B. Moss , MD, ... former Director of the Cystic Fibrosis Center at Stanford University, ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology: